| Phase 3 |
| NCT04184505 |
Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT) |
High-risk MDS |
Recruiting |
2025-04-29 |
| NCT04168502 |
Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML |
Acute Myeloid Leukemia |
Recruiting |
2024-11-08 |
| NCT04722848 |
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in… |
Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) |
Active, Not Recruiting |
2025-01-23 |
| Phase 2 |
| NCT06409936 |
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML |
CML, Chronic Phase |
Recruiting |
2025-07-08 |
| NCT05694312 |
Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL |
Autoimmune Hemolytic Anemia |
Recruiting |
2023-12-01 |
| NCT03610438 |
Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic… |
Acute Lymphoid Leukemia |
Active, Not Recruiting |
2026-07-16 |
| NCT05478512 |
Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With… |
High Risk CLL |
Active, Not Recruiting |
2026-03-17 |
| NCT05306301 |
Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients |
Chemotherapy |
Active, Not Recruiting |
2026-03-06 |
| NCT06253637 |
Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program |
T-Lymphocytic Leukemia, Acute |
Active, Not Recruiting |
2026-03-05 |
| NCT06880601 |
Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple… |
Multiple Myleoma |
Not Yet Recruiting |
2025-04-03 |
| NCT06667973 |
Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive… |
Acute Myeloid Leukemia |
Not Yet Recruiting |
2025-03-12 |
| NCT04763928 |
Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating… |
Acute Myeloid Leukemia |
Active, Not Recruiting |
2024-11-08 |
| NCT04475731 |
Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse |
Philadelphia-Positive ALL |
Active, Not Recruiting |
2024-10-22 |
| Not applicable |
| NCT04587856 |
Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS… |
Myelodysplastic Syndromes |
Recruiting |
2024-10-22 |
| NCT05694325 |
Biologic Characterization of Patients With ITP |
Immune Thrombocytopenia |
Recruiting |
2024-05-21 |
| NCT05839392 |
Novel Approaches to Target MECOM/EVI1 in AML |
AML, Adult |
Recruiting |
2023-12-29 |
| NCT07867704 |
Feasibility and Efficiency Study for the Implementation of a New Screening Method for… |
Acute Myeloid Leukemia |
Not Yet Recruiting |
2026-10-09 |
| NCT04460963 |
Role of Adrenomedullin in Leukemic Endosteal/Vascular Niches |
Acute Myeloid Leukemia |
Active, Not Recruiting |
2026-03-06 |
| NCT07158294 |
Identification of BCR::ABL1 Mutations by Digital PCR in CML |
Chronic Myeloid Leukemia (CML) |
Not Yet Recruiting |
2025-09-05 |
| NCT06364033 |
Biological and Clinical Efficacy of Shingrix in Patients With CLL |
Chronic Lymphocytic Leukemia |
Not Yet Recruiting |
2024-05-09 |
| NCT06090786 |
Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and… |
AML, Adult |
Not Yet Recruiting |
2024-04-10 |
| Not specified |
| NCT07080970 |
Observational Study on APL-like aCute Myeloid Leukemia: disTInct Phenotype and Early… |
Acute Myeloid Leukemia |
Recruiting |
2026-06-22 |
| NCT06933277 |
Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for… |
Multiple Myeloma |
Recruiting |
2025-09-10 |
| NCT06513273 |
Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life… |
Acute Myeloid Leukemia |
Recruiting |
2025-08-13 |
| NCT06657846 |
HRQoL and Financial Toxicity in Patients With VEXAS Syndrome |
VEXAS |
Recruiting |
2025-07-15 |